BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide ... | May 6, 2023
Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide ... | May 6, 2023
BeiGene (NASDAQ:BGNE – Get Rating) posted its earnings results on Thursday. The company reported ($3.34) earnings per share for the quarter, topping the consensus estimate of ($3.66) by $0.32, Briefing.com reports. The firm had revenue of $447.80 million for the quarter, compared to analyst estimates of $449.44 million. BeiGene had a negative return on equity […]
Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA in the U.S. for adult patients with chronic lymphocytic
Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA® in the U.S. for adult patients with chronic... | May 4, 2023
100% Tumor Shrinkage at 2-months in advanced metastatic colorectal cancer was demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 Antibody Tislelizumab combination in the first, lowest dose cohort ... | May 3, 2023